The MIF gene has been associated with several diseases with inflammatory and autoimmune background, such as ulcerative colitis, rheumatoid arthritis and systemic lupus erythematosus. We aimed at testing the influence of two functional MIF promoter variants in celiac disease (CD) susceptibility. A (CAAT) 5-8 tetranucleotide repeat at position À794 and a singlenucleotide polymorphism at À173G/C were analyzed in the Spanish population (531 patients and 887 healthy controls). w 2 statistics or Fisher exact test were used for comparisons. The À173C allele significantly increased risk ((CC þ GC) vs GG: odds ratio (OR) (95% confidence interval (CI)) ¼ 1.41 (1.10-1.81); P ¼ 0.005), as did carriage of the (CAAT) 7 allele (OR (95% CI) ¼ 1.36 (1.02-1.82); P ¼ 0.03) and of the haplotype (CAAT) 7 //À173C (OR (95% CI) ¼ 1.33 (1.00-1.76); P ¼ 0.04). Our data evidence for first time the role of the MIF gene increasing predisposition to CD. A common effect of MIF variants seems to underlie the etiology of these complex conditions.
Introduction
Celiac disease (CD) predisposition is primarily determined by peptide-presenting human leukocyte antigen (HLA) alleles (DQ2 and DQ8) and one of the bestcharacterized environmental factors (gliadin) for any common autoimmune disease. 1 Based on population screening, its prevalence has been estimated in 1%. 2 The abnormal immune response in the small intestine leads to a series of histological changes resulting in lymphocytosis, crypt hyperplasia and villous atrophy. 3 Although the genetic susceptibility to this chronic inflammatory disorder is increased by the aforementioned HLA risk alleles present in approximately 95% of CD patients and only 20-30% healthy controls, 4 this risk factor only explains part of the familial aggregation observed, and its consideration as a complex disease is generally accepted. Therefore, the search for other candidate genes altering the genetic predisposition to the disease is necessary for a better understanding of this condition and ultimately, for a specific targeted therapy.
Migration inhibitory factor (MIF), a cytokine cloned in 1989, 5 is a peptide released by the pituitary gland after exposure to endotoxin. 6 MIF is constitutively expressed by a variety of cells such as monocytes/macrophages, 7 eosinophils, 8 epithelial cells, 9, 10 etc. This modulator of both inflammatory and immune responses 11 is encoded by a gene located on human chromosome 22q11. 12 The MIF gene presents high degree of conservation across different species, suggestive of the importance of its biological function. 13 The mechanisms by which gluten/ gliadin damages the intestinal mucosa of patients with CD remain unclear. Gluten peptides are absorbed across the epithelium, presented in association with HLA class II (HLA-DQ2) molecules by macrophages in the lamina propria, and recognized by CD4 þ T cells. Therefore, epithelial cells are the first cells to contact with gliadin peptides and they can act as sentinels initiating the proinflammatory response. In this sense, increased intracellular levels of MIF have been found in epithelial cells of celiac patients compared with healthy controls (P ¼ 0.005 14 ) . We aimed at testing the etiological role of this gene in celiac susceptibility through a case-control study with 531 Spanish celiac patients and 887 healthy controls of the same ethnic background. The À173G/C MIF polymorphism was identified in 2001 by Donn et al. 15 The presence of a cytosine at À173 creates a binding site for the transcription factor AP4, which may affect gene expression. Previous results about the activity of the MIF promoter in different cell types suggest that this variant may act in a cell-specific manner. 16 The analysis of a (CAAT) [5] [6] [7] [8] tetranucleotide repeat at position À794 will allow to perform the haplotypic association of the gene with this enteropathy. Strong linkage disequilibrium has been reported between the (CAAT) 7 and À173C alleles, and this haplotype has been found associated with several autoimmune diseases. We sought to verify whether these MIF susceptibility markers for autoimmune diseases play also a role in celiac predisposition.
Results and discussion Table 1 summarizes the genotypic frequencies of the two promoter markers studied in a total of 531 CD patients and 887 ethnically matched healthy controls. All these samples were collected in three Spanish centers (Hospital Clínico San Carlos, Madrid; Hospital La Paz, Madrid and Hospital Virgen de las Nieves, Granada) after obtaining informed consent and include only participants of Spanish white origin. Celiac patients were diagnosed following the European Society for Paedriatic Gastroenterology and Nutrition (ESPGAN) criteria. 17 The mean age for diagnosis was 2.772.7 and a total of 60% were women. This study was approved by the local ethical committees of all the hospitals involved in the study.
All polymorphisms conformed to Hardy-Weinberg expectations in controls. An overall different distribution of À173G/C genotypes was found between both groups (w 2 ¼ 8.64; P ¼ 0.013) and the À173C allele significantly increased risk (odds ratio (OR) (95% confidence interval (CI)) ¼ 1.31 (1.05-1.63); P ¼ 0.014; carriage of À173C: OR (95% CI) ¼ 1.41 (1.10-1.81); P ¼ 0.005). Carriers of allele (CAAT) 7 were also significantly increased in patients (OR (95% CI) ¼ 1.36 (1.02-1.82); P ¼ 0.03). There is a strong linkage disequilibrium between À173C and (CAAT) 7 in our population (D 0 ¼ 0.97). The (CAAT) 7 //À173C susceptibility haplotype has been found associated with other autoimmune inflammatory diseases such as juvenile idiopathic arthritis, systemic lupus erythematosus or psoriasis. When this haplotype was tested in our CD cohort, significant difference with ethnically matched healthy controls was observed (Table 2) . A protective effect has been previously described for the (CAAT) 5 // À173G haplotype, which also showed a trend for protection towards CD in our population (Table 2 ). No significant difference was observed between HLA-DQ2-positive (92% of the CD patients) and HLA-DQ2-negative celiac patients, although the low number of HLA-DQ2-negative CD patients precluded a conclusive result (data not shown).
This work supports a partial role of the MIF gene on CD development. Elevated levels of MIF were reported in the mucosa of CD patients on a gluten-free diet: in duodenal biopsy specimens, intracellular levels of MIF in epithelial cells were significantly raised when compared Abbreviations: CD, celiac disease; MIF, migration inhibitory factor. The À173G/C MIF single-nucleotide polymorphism (rs755622) was analyzed by a TaqMan Assay-on-Demand (C___2213785_10) in a 7900HT Real-Time polymerase chain reaction (PCR) System from Applied Biosystems following the manufacturer's suggestions (Foster City, CA, USA). The alleles of the tetranucleotide repeat microsatellite were discriminated by capillary electrophoresis on an ABI 3100 (Applied Biosystems) after PCR amplification with the following primers: forward: 5 0 -FAM -TTG CAC CTA TCA GAG ACC-3 0 ; and reverse: 5 0 -TCC ACT AAT GGT AAA CTC G-3 0 . The laboratory staff was blinded to the clinical status of the sample analyzed, and the rate of samples genotyped was over 98%. Frequency comparions were performed by applying the w 2 statistics or Fisher exact test when necessary. The genotype association with CD was estimated by the odds ratio (OR) with 95% confidence interval (CI). Statistical analysis used Epi Info v. 6.02 (CDC, Atlanta, USA). Abbreviations: CD, celiac disease; MIF, migration inhibitory factor. Haplotypic frequencies were estimated using the expectation-maximization (EM) algorithm 25 implemented in the Arlequin v2.000 software, with number of iterations set at 5000 and initial conditions at 50, with an epsilon value of 10
À7
. As our goal was to confirm in CD the susceptibility effect of the two MIF polymorphisms already reported in other inflammatory autoimmune diseases, Bonferroni's correction was not applied in any case.
with controls.
14 However, evidence exists of an incomplete recovery of normal mucosa in celiac patients despite a gluten-free diet and a residual inflammation could persist. [18] [19] [20] Our data suggest that the reported MIF levels would not be a consequence of the inflammatory process, but they would be directly involved in the etiology of the disease. Functional studies on the role of the polymorphisms tested have been performed in the past with controversial findings reported in different cell types; [21] [22] [23] however, the (CAAT) 5 allele was associated with reduced basal and serum/forskolin-stimulated transcriptional activity in vitro [21] [22] [23] and the (CAAT) 7 and À173C alleles emerged as probable upregulators of transcriptional activity. 24 The identification of new CD susceptibility genes may provide novel insights into its pathogenesis and explanations for the clinical heterogeneity of the disease. Replication in independent populations is warranted for the firm establishment of the observed role of MIF in our population, suggestive of the active part of the gene in the autoimmune disease process.
